Vigil Neuroscience Inc Provided An Update On Company's Small Molecule Trem2 Agonist, Vg-3927

Reuters
2023.10.12 20:21
portai
I'm PortAI, I can summarize articles.

Oct 12 (Reuters) - Vigil Neuroscience Inc:

Oct 12 (Reuters) - Vigil Neuroscience Inc (VIGL.O) :

  • VIGIL NEUROSCIENCE INC - PROVIDED AN UPDATE ON COMPANY’S SMALL MOLECULE TREM2 AGONIST, VG-3927

  • VIGIL NEUROSCIENCE - GOT 30-DAY RESPONSE LETTER FROM U.S. FDA REGARDING PREVIOUSLY COMMUNICATED PARTIAL CLINICAL HOLD ON IND APPLICATION FOR VG-3927

  • VIGIL NEUROSCIENCE - LETTER SAYS EXTRA NON-CLINICAL DATA NEEDS TO BE PROVIDED TO EXCEED MAXIMUM EXPOSURE LIMIT IN PHASE 1 TRIAL EVALUATING VG-3927

  • VIGIL NEUROSCIENCE INC - IN PROCESS OF OBTAINING ADDITIONAL PHARMACOKINETIC DATA AND WILL WORK WITH FDA TO ADDRESS PARTIAL CLINICAL HOLD Further company coverage: (VIGL.O)

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.